Cargando…
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
Psoriasis management may be challenging, particularly for moderate-to-severe forms of the disease. Indeed, conventional systemic treatments are often avoided for contraindications or the risk of adverse events as well as phototherapy is often limited by logistic concerns. Despite the development of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166089/ https://www.ncbi.nlm.nih.gov/pubmed/37168605 http://dx.doi.org/10.2147/PTT.S407647 |
_version_ | 1785038372997169152 |
---|---|
author | Potestio, Luca Ruggiero, Angelo Fabbrocini, Gabriella Martora, Fabrizio Megna, Matteo |
author_facet | Potestio, Luca Ruggiero, Angelo Fabbrocini, Gabriella Martora, Fabrizio Megna, Matteo |
author_sort | Potestio, Luca |
collection | PubMed |
description | Psoriasis management may be challenging, particularly for moderate-to-severe forms of the disease. Indeed, conventional systemic treatments are often avoided for contraindications or the risk of adverse events as well as phototherapy is often limited by logistic concerns. Despite the development of biological drugs and small molecules revolutionized the treatment options showing promising results in terms of safety and effectiveness, some limitations remain. Thus, there is still a need for new therapies that are always welcome in order to tailor the treatment to the patient and to have a higher level of performance, especially in order to maintain long-term effectiveness. In this scenario, deucravacitinib, an oral small molecule which selectively inhibits Tyrosine Kinase 2, may represent a promising weapon in psoriasis management. The aim of our manuscript is to review the current knowledge on the efficacy and safety of deucravacitinib for the management of psoriasis. |
format | Online Article Text |
id | pubmed-10166089 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-101660892023-05-09 Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature Potestio, Luca Ruggiero, Angelo Fabbrocini, Gabriella Martora, Fabrizio Megna, Matteo Psoriasis (Auckl) Review Psoriasis management may be challenging, particularly for moderate-to-severe forms of the disease. Indeed, conventional systemic treatments are often avoided for contraindications or the risk of adverse events as well as phototherapy is often limited by logistic concerns. Despite the development of biological drugs and small molecules revolutionized the treatment options showing promising results in terms of safety and effectiveness, some limitations remain. Thus, there is still a need for new therapies that are always welcome in order to tailor the treatment to the patient and to have a higher level of performance, especially in order to maintain long-term effectiveness. In this scenario, deucravacitinib, an oral small molecule which selectively inhibits Tyrosine Kinase 2, may represent a promising weapon in psoriasis management. The aim of our manuscript is to review the current knowledge on the efficacy and safety of deucravacitinib for the management of psoriasis. Dove 2023-05-04 /pmc/articles/PMC10166089/ /pubmed/37168605 http://dx.doi.org/10.2147/PTT.S407647 Text en © 2023 Potestio et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Potestio, Luca Ruggiero, Angelo Fabbrocini, Gabriella Martora, Fabrizio Megna, Matteo Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature |
title | Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature |
title_full | Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature |
title_fullStr | Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature |
title_full_unstemmed | Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature |
title_short | Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature |
title_sort | effectiveness and safety of deucravacitinib for the management of psoriasis: a review of the current literature |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166089/ https://www.ncbi.nlm.nih.gov/pubmed/37168605 http://dx.doi.org/10.2147/PTT.S407647 |
work_keys_str_mv | AT potestioluca effectivenessandsafetyofdeucravacitinibforthemanagementofpsoriasisareviewofthecurrentliterature AT ruggieroangelo effectivenessandsafetyofdeucravacitinibforthemanagementofpsoriasisareviewofthecurrentliterature AT fabbrocinigabriella effectivenessandsafetyofdeucravacitinibforthemanagementofpsoriasisareviewofthecurrentliterature AT martorafabrizio effectivenessandsafetyofdeucravacitinibforthemanagementofpsoriasisareviewofthecurrentliterature AT megnamatteo effectivenessandsafetyofdeucravacitinibforthemanagementofpsoriasisareviewofthecurrentliterature |